Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LSL Pharma Group Inc ( (TSE:LSL) ) has provided an announcement.
LSL Pharma Group Inc. has completed the $5 million acquisition of Toronto-based Juno OTC Inc. from Juno Pharmaceuticals LP, gaining full legal ownership immediately and scheduled to assume operational control on January 1, 2026. The deal, structured as an arm’s‑length expedited acquisition on the TSX Venture Exchange and partly paid in cash and LSL shares, strengthens LSL’s footprint in the Canadian private-label OTC consumer healthcare segment by integrating a key supplier to major retailers. Concurrently, LSL closed a $2 million non-brokered private placement of unsecured convertible debentures, of which $1.5 million was subscribed by the seller, bringing total gross proceeds from its brokered and non-brokered offerings to $12 million and providing additional capital to support the acquisition and broader growth initiatives.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company listed on the TSX Venture Exchange that develops, manufactures and distributes health-related products. The acquisition of Juno OTC adds a leading supplier in Canada’s private label consumer healthcare over-the-counter (OTC) market, which serves major retailers with branded-equivalent products and relies on strong regulatory and quality assurance capabilities under Health Canada requirements.
Average Trading Volume: 68,591
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$43.64M
Find detailed analytics on LSL stock on TipRanks’ Stock Analysis page.